Legal News

Supreme Court considers test for obviousness of dosage patent (Actavis Group PTC EHF and others v Icos Corporation and another)

Supreme Court considers test for obviousness of dosage patent (Actavis Group PTC EHF and others v Icos Corporation and another)
Published on: 01 April 2019
Published by: LexisPSL
  • Supreme Court considers test for obviousness of dosage patent (Actavis Group PTC EHF and others v Icos Corporation and another)
  • What are the practical implications of the judgment?
  • What was the background?
  • What did the Supreme Court decide?
  • Test for obviousness of dosage patent
  • Court of Appeal’s ability to reverse finding of obviousness

Article summary

IP analysis: Robert Burrows, partner, and Rachel Mumby and Claire Phipps-Jones, senior associates, at Bristows, examine the Supreme Court’s decision in Actavis Group PTC EHF and others v Icos Corporation and another establishing that the Court of Appeal had been entitled to reverse the Patents Court’s decision that the appellants’ patent relating to the optimal dosage of a drug used to treat erectile dysfunction involved an inventive step. or take a trial to read the full analysis.

Popular documents